AgomAb Therapeutics NV (AGMB)

Market Cap	513.69M
Revenue (ttm)	n/a
Net Income	-84.79M
EPS	-3,391.53
Shares Out	48.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,482
Open	10.41
Previous Close	10.21
Day's Range	10.18 - 11.25
52-Week Range	9.00 - 17.45
Beta	n/a
Analysts	Buy
Price Target	32.00 (+203.61%)
Earnings Date	Jun 16, 2026

About AGMB

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2026
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: AGMB
• Website: https://agomab.com

Financial Performance

Financial numbers in EUR

Analyst Summary

According to 3 analysts, the average rating for AGMB stock is "Buy." The 12-month stock price target is $32.0, which is an increase of 203.61% from the latest price.

Price Target

$32.0

(203.61% upside)

Analyst Consensus: Buy